Banking service chronicle published this article page no 5 the drug works by blocking the action of two viral proteins preventing the virus from replicating. importantly it was well-tolerated by all trial participants.a critical question for the future is how to ensure access to the new drug particularly in low- and middle-income countries where it is urgently needed.this challenge echoes the issues surrounding the dengue vaccine endorsed by the world health organization earlier this month where equitable access remains a concern Banking service chronicle magazine subscription.
No comments:
Post a Comment